QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Forecast, Price & News

$38.47
-0.42 (-1.08%)
(As of 09/26/2023 ET)
Compare
Today's Range
$38.14
▼
$39.30
50-Day Range
$37.50
▼
$44.03
52-Week Range
$29.85
▼
$59.46
Volume
769,176 shs
Average Volume
1.26 million shs
Market Capitalization
$5.07 billion
P/E Ratio
22.50
Dividend Yield
N/A
Price Target
$54.27
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
41.1% Upside
$54.27 Price Target
Short Interest
Healthy
5.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.71mentions of Halozyme Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$4.23 M Sold Last Quarter
Proj. Earnings Growth
44.35%
From $2.48 to $3.58 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.13 out of 5 stars

Medical Sector

18th out of 964 stocks

Biological Products, Except Diagnostic Industry

3rd out of 158 stocks

See Top Rated MarketRank™ Stocks Here

HALO stock logo

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Price History

HALO Stock News Headlines

September 26, 2023 | americanbankingnews.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by Brokerages
September 20, 2023 | finance.yahoo.com
Insider Sell: SVP, Chief Technical Officer Michael Labarre Sells 10,000 Shares of Halozyme ...
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 12, 2023 | msn.com
Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA Setback
September 12, 2023 | finance.yahoo.com
ReNAgade Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
September 7, 2023 | finance.yahoo.com
Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?
September 5, 2023 | finance.yahoo.com
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
September 1, 2023 | finance.yahoo.com
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 31, 2023 | msn.com
HC Wainwright & Co. Reiterates Halozyme Therapeutics (HALO) Buy Recommendation
August 30, 2023 | finance.yahoo.com
Should You Remain Confident in Halozyme Therapeutics (HALO)?
August 29, 2023 | finance.yahoo.com
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
August 15, 2023 | msn.com
HC Wainwright & Co. Maintains Halozyme Therapeutics (HALO) Buy Recommendation
August 15, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for Halozyme (HALO)
August 15, 2023 | markets.businessinsider.com
Expert Ratings for Halozyme Therapeutics
August 10, 2023 | seekingalpha.com
Halozyme Therapeutics, Inc. (HALO) Q2 2023 Earnings Call Transcript
August 9, 2023 | finance.yahoo.com
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
August 9, 2023 | markets.businessinsider.com
Goldman Sachs Sticks to Its Hold Rating for Halozyme (HALO)
August 9, 2023 | finance.yahoo.com
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
August 8, 2023 | msn.com
Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.10, revenue of $221.04M beats by $21.09M
August 8, 2023 | finance.yahoo.com
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
August 8, 2023 | finance.yahoo.com
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
August 8, 2023 | seekingalpha.com
Halozyme Therapeutics Q2 2023 Earnings Preview
July 28, 2023 | reuters.com
Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
July 25, 2023 | finance.yahoo.com
Halozyme To Report Second Quarter 2023 Financial and Operating Results
July 25, 2023 | nasdaq.com
HC Wainwright & Co. Initiates Coverage of Halozyme Therapeutics (HALO) with Buy Recommendation
July 25, 2023 | msn.com
Goldman Sachs Downgrades Halozyme Therapeutics (HALO)
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
CIK
1159036
Web
www.halozyme.com
Phone
858-794-8889
Fax
858-704-8311
Employees
393
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$54.27
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+41.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$1.71
Trailing P/E Ratio
22.46
Forward P/E Ratio
15.48
P/E Growth
0.61
Net Income
$202.13 million
Net Margins
30.21%
Pretax Margin
37.47%
Return on Equity
254.75%
Return on Assets
17.08%

Debt

Debt-to-Equity Ratio
9.91
Current Ratio
6.58
Quick Ratio
5.44

Sales & Book Value

Annual Sales
$660.12 million
Price / Sales
7.67
Cash Flow
$2.52 per share
Price / Cash Flow
15.26
Book Value
$1.26 per share
Price / Book
30.48

Miscellaneous

Outstanding Shares
131,920,000
Free Float
128,887,000
Market Cap
$5.07 billion
Optionable
Optionable
Beta
1.24

Social Links

7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 60)
    M.R.C.P., Pres, CEO & Director
    Comp: $1.45M
  • Ms. Nicole LaBrosseMs. Nicole LaBrosse (Age 40)
    Sr. VP & CFO
    Comp: $727.04k
  • Dr. Michael J. LaBarre Ph.D. (Age 59)
    Sr. VP & Chief Technical Officer
    Comp: $723.24k
  • Mr. Mark Snyder Esq.
    Chief Legal Officer
  • Ms. Tram Bui
    Head of Investor Relations & Corp. Communications
  • Ms. Amy Marinne Fox
    Chief HR Officer
  • Dr. Steve Knowles MBBS
    Chief Medical Officer
  • Dr. Christopher Bryant Ph.D. (Age 62)
    Chief Manufacturing Officer & Head of Technical Operations
  • Ms. Kristin Schwartzbauer
    Head of Quality
  • Mr. Gary Grote
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.

What is Halozyme Therapeutics' stock price forecast for 2023?

11 Wall Street analysts have issued twelve-month price objectives for Halozyme Therapeutics' shares. Their HALO share price forecasts range from $42.00 to $68.00. On average, they expect the company's stock price to reach $54.27 in the next year. This suggests a possible upside of 41.3% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2023?

Halozyme Therapeutics' stock was trading at $56.90 at the beginning of 2023. Since then, HALO stock has decreased by 32.5% and is now trading at $38.40.
View the best growth stocks for 2023 here.

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 6,840,000 shares, a drop of 6.3% from the August 15th total of 7,300,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is currently 6.6 days. Currently, 5.2% of the shares of the company are short sold.
View Halozyme Therapeutics' Short Interest.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our HALO earnings forecast.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.09. The biopharmaceutical company earned $221.04 million during the quarter, compared to analyst estimates of $201.91 million. Halozyme Therapeutics had a trailing twelve-month return on equity of 254.75% and a net margin of 30.21%.

What ETFs hold Halozyme Therapeutics' stock?

ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Long/Short ETF (FFLS), Future Fund Active ETF (FFND), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), BlackRock Future Innovators ETF (BFTR), Invesco S&P MidCap 400 Pure Growth ETF (RFG), SPDR S&P Biotech ETF (XBI) and Goldman Sachs Future Health Care Equity ETF (GDOC).

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $2.65-$2.75 for the period, compared to the consensus estimate of $2.61. The company issued revenue guidance of $825.00 million-$845.00 million, compared to the consensus revenue estimate of $823.06 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (5.66%), Snyder Capital Management L P (3.28%), Geode Capital Management LLC (2.07%), Marshall Wace LLP (1.76%), Thrivent Financial for Lutherans (1.58%) and Northern Trust Corp (1.53%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $38.40.

How much money does Halozyme Therapeutics make?

Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $5.07 billion and generates $660.12 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.71 on an earnings per share basis.

How many employees does Halozyme Therapeutics have?

The company employs 393 workers across the globe.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -